Thailand Medical News - For All The Latest Breaking Medical News, Health News, Research News, COVID-19 News, Outbreak News, Dengue News, Glaucoma News, Diabetes News, Herb News, Phytochemical News, Heart And Cardiology News, Epigenetic News, Cancer News,

BREAKING NEWS
Source: COVID-19 Immunology  Aug 21, 2020  3 years, 7 months, 3 weeks, 6 days, 17 hours, 9 minutes ago

BREAKING! COVID-19 Immunology: Could SARS-CoV-2 Be Depleting, Altering or Even Destroying CD8 Cells? New Australian Study Suspects So

BREAKING! COVID-19 Immunology: Could SARS-CoV-2 Be Depleting, Altering or Even Destroying CD8 Cells? New Australian Study Suspects So
Source: COVID-19 Immunology  Aug 21, 2020  3 years, 7 months, 3 weeks, 6 days, 17 hours, 9 minutes ago
COVID-19 Immunology: Australian scientist from Monash University, the University of Melbourne and James Cook University have made a disturbing discovery that infection with the SARS-CoV-2 coronavirus might compromise the activation of the CD8+ T-cell responses that would usually ameliorate disease and drive recovery. 


 
The research findings are published on a preprint server and are currently being peer-reviewed. https://www.medrxiv.org/content/10.1101/2020.08.17.20176370v1
 
Lead researcher Dr Katherine Kedzierska from the department of Microbiology and Immunology at University of Melbourne and the rest of the co-researchers, by utilizing a combination of peptide prediction and in vitro peptide stimulation, found that while SARS-CoV-2 infection did stimulate CD4+ T-cell responses that were comparable to those seen with other viral infections, the CD8+ T cells that would usually target the virus were at extremely low prevalence and less than optimal phenotype for viral elimination.
 
It was estimated that the SARS-CoV-2-specific response was ten times lower than would usually be found for CD8+ T-cells targeting the viral Epstein-Barr Virus (EBV) or influenza A (IAV), as examples.
 
The study team says further research is needed to provide a more detailed understanding of CD8+ T-cell responses to the SARS-CoV-2 coronavirus since priming with an appropriate vaccine could be highly valuable in terms of optimizing protective CD8+ T-cell immunity.
 
While the majority of infections only cause mild disease and are short-lived, around 12 to 18% of patients with COVID-19 develop severe disease and require hospitalization.
 
What is even worrisome is that of those who do develop mild disease or are even asymptomatic, the underlying pathology may still be present.
 
To date, a lot remains unknown about the immune response to COVID-19, and an improved understanding is urgently needed if any immunopathology is going to be managed appropriately and vaccine development optimized.
 
It is generally known that virus-specific CD8+ T-cells play a role in clearing viral infection in the acute immune response to respiratory infection, where an established CD8+ T-cell memory response provides future protection against severe disease.
 
For example, survivors of the 2002-3 SARS-CoV-1 outbreak, for example, still maintain populations of CD4+ and CD8+ cells that are specific to the virus.
 
In the case of SARS-CoV-2, evidence suggests that virus-specific T-cells are being produced. A previous study by Kedzierska and team found CD4+ T-follicular helper cells and activated CD38+ HLA-DR+ CD8+ T-cells in the blood of patients with COVID-19 three days before recovery, suggesting that these cells were involved in resolving disease. (off course anomalies could also be attributed to mutating variants displaying other new characteristics.)
 
But there was also another study that showed that some of the SARS-CoV-2 specific CD8+ T